Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PathoQuest and Covance to Offer NGS-based Biosafety Assessments

Published: Thursday, November 07, 2013
Last Updated: Wednesday, November 06, 2013
Bookmark and Share
Unique technology for virus screening in a single comprehensive assay to overcome the current limitations with predefined sets of known viruses.

Covance Inc. and PathoQuest have announced an exclusive agreement to collaborate in providing Next-Generation Sequencing (NGS) based biosafety assessments.

This innovative biosafety testing approach, combined with Covance’s regulatory expertise, provides a flexible testing solution to all biotherapeutic clients and makes biologic medicines safer.

Since viral contamination poses a significant potential safety risk to patients, regulatory agencies are increasingly focusing on the use of advanced analytical technologies like NGS for detection of viral contaminants.

The new NGS-based platform can detect and identify viral contaminants within biologic compounds (such as monoclonal antibodies or vaccines) throughout the entire lifecycle of the product.

“This collaboration will provide Covance clients with a high-quality solution to the critical problem of viral contamination of biologics during development and in released product,” said Raymond Kaiser PhD, global vice president of Biopharmaceutical Chemistry, Manufacturing and Control (CMC) Solutions for Covance.

Kaiser continued, “As a cutting-edge company in the field of NGS-based virus identification, PathoQuest’s capability dovetails perfectly with our CMC analytical solutions to provide our clients access to the latest technology and patients with safer medications.”

“Covance’s global footprint and extensive experience in BioCMC development, together with their established in-house biosafety testing capabilities, offer perfect synergies to help clients access our NGS-based adventitious assay globally. In an evolving regulatory environment, we anticipate that NGS will soon become the standard approach in biosafety assessment. Our technology will help clients meet that standard now and well into the future,” said Luc Boblet PhD, co-founder and CEO of PathoQuest.

The industry is increasingly adopting the technology, with several high-profile instances of viral contamination of commercially released biologic drugs detected by NGS.

The NGS solution offered by Covance and PathoQuest overcomes the primary limitation of traditional approaches that only identify a predefined short list of viruses. In contrast, this new solution provides a universal test for identifying any virus in a single, comprehensive analysis that minimizes false negatives.

Covance and PathoQuest will provide clients with a wide range of options for adventitious virus identification. This includes a rapid detection protocol for the critical evaluation of major issues within production processes and a more comprehensive approach for development and characterization of cell banks and biological production systems.

For small, emerging and virtual biotech companies, representing a growing and valued segment of Covance’s client base, this solution allows them access to a unique technology early in the development process that will increase the value and safety profile of their molecule.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Antibiotics Discovered While Sifting Through Human Microbiome
Researchers identify genes in a microbe’s genome that produce antibiotic compounds, then synthesize them without the need for bacterial culture.
A Genome-wide View of Human DNA Viruses
In this study, Duplex sequencing was used to accurately analyse the genome-wide rate of spontaneous mutation of human adenovirus C5 (HAdv5).
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Rare Immunodeficiency Yields Unexpected Insights
Scientists uncover previously unknown gene mutation revealing the role of a key molecule involved in immune cell development.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!